At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.

Health Care

Life Sciences

Therapeutics

Avid Radiopharmaceuticals

Ian Halvorsen

David Wilson

Lisaann Trembath

Kelly Conway

Amanda Morris

Marybeth Devine

Caitlin Pearson

Christine Gallagher

Luckens Osias

Anne McGeehan

Carey Horchler

Robert Morrison

The Research and Development team at Avid Radiopharmaceuticals focuses on creating innovative molecular imaging agents aimed at early detection and management of chronic diseases, particularly those affecting the central nervous system. This diverse group of experts, including chemists, scientists, and statisticians, collaborates on the synthesis, testing, and regulatory pathways of imaging compounds, driving advancements that could lead to transformative changes in clinical practices for conditions like Alzheimer's and Parkinson's disease. Their work supports the overarching mission of enabling pre-symptomatic diagnosis and personalized treatment options.

Research and Development

Operations and Support

Clinical Operations and Management

Research and Development

About

Team members

Other teams at Avid Radiopharmaceuticals

Operations and Support

Clinical Operations and Management